707 related articles for article (PubMed ID: 34461483)
21. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
22. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
[TBL] [Abstract][Full Text] [Related]
23. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular events after the initiation of immune checkpoint inhibitors.
Suzuki Y; Kaneko H; Tamura Y; Okada A; Fujiu K; Michihata N; Takeda N; Jo T; Morita H; Node K; Yasunaga H; Komuro I
Heliyon; 2023 May; 9(5):e16373. PubMed ID: 37251893
[TBL] [Abstract][Full Text] [Related]
25. Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors - A nationwide population-based cohort study.
Kim HW; Kim JS; Lee SH
Lung Cancer; 2021 Aug; 158():107-114. PubMed ID: 34146757
[TBL] [Abstract][Full Text] [Related]
26. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
[TBL] [Abstract][Full Text] [Related]
27. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
[TBL] [Abstract][Full Text] [Related]
29. Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy.
Ge W; Wu N; Jalbert JJ; Quek RGW; Liu J; Rietschel P; Pouliot JF; Harnett J; Hsu ML; Feliciano JL
Cancer Manag Res; 2022; 14():3191-3202. PubMed ID: 36415537
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week.
Ball S; Ghosh RK; Wongsaengsak S; Bandyopadhyay D; Ghosh GC; Aronow WS; Fonarow GC; Lenihan DJ; Bhatt DL
J Am Coll Cardiol; 2019 Oct; 74(13):1714-1727. PubMed ID: 31558256
[TBL] [Abstract][Full Text] [Related]
31. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer.
Leapman MS; Presley CJ; Zhu W; Soulos PR; Adelson KB; Miksad RA; Boffa DJ; Gross CP
JAMA Netw Open; 2020 Jun; 3(6):e207205. PubMed ID: 32511721
[TBL] [Abstract][Full Text] [Related]
32. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
[TBL] [Abstract][Full Text] [Related]
33. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
[TBL] [Abstract][Full Text] [Related]
34. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
35. The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study.
Lev-Ari S; Serzan M; Wu T; Ip A; Pascual L; Sinclaire B; Adams S; Marafelias M; Ayyagari L; Gill SK; Ma B; Zaemes JP; Della Pia A; Alaoui A; Madhavan S; Belouali A; Pecora A; Ahn J; Atkins MB; Shah NJ
Cancer; 2023 Jun; 129(12):1885-1894. PubMed ID: 36951119
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma.
L'Orphelin JM; Dollalille C; Akroun J; Alexandre J; Dompmartin A
Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046831
[TBL] [Abstract][Full Text] [Related]
37. Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis.
Horiuchi K; Ikemura S; Sato T; Shimozaki K; Okamori S; Yamada Y; Yokoyama Y; Hashimoto M; Jinzaki M; Hirai I; Funakoshi T; Mizuno R; Oya M; Hirata K; Hamamoto Y; Terai H; Yasuda H; Kawada I; Soejima K; Fukunaga K
Oncologist; 2024 Jan; 29(1):e108-e117. PubMed ID: 37590388
[TBL] [Abstract][Full Text] [Related]
38. Association of age with survival in older patients with cutaneous melanoma treated with immune checkpoint inhibitors.
Howell AV; Gebregziabher M; Thiers BH; Graboyes EM; Paulos CM; Wrangle JM; Hunt KJ; Wallace K
J Geriatr Oncol; 2022 Sep; 13(7):1003-1010. PubMed ID: 35660090
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.
Shi Y; Fang J; Zhou C; Liu A; Wang Y; Meng Q; Ding C; Ai B; Gu Y; Yao Y; Sun H; Guo H; Zhang C; Song X; Li J; Xu B; Han Z; Song M; Tang T; Chen P; Lu H; Shui Y; Lou G; Zhang D; Liu J; Liu X; Liu X; Gao X; Zhou Q; Chen M; Zhao J; Zhong W; Xu Y; Wang M
Thorac Cancer; 2022 Feb; 13(3):412-422. PubMed ID: 34935288
[TBL] [Abstract][Full Text] [Related]
40. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study.
D'Souza M; Nielsen D; Svane IM; Iversen K; Rasmussen PV; Madelaire C; Fosbøl E; Køber L; Gustafsson F; Andersson C; Gislason G; Torp-Pedersen C; Schou M
Eur Heart J; 2021 Apr; 42(16):1621-1631. PubMed ID: 33291147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
